The Siteman Cancer Center has placed the highest priority on ensuring the safety of patients participating in clinical trials. The SCC Data and Safety Monitoring Plan (NCI-approved in 2002) was developed to coordinate and provide oversight for data and safety monitoring for all cancer-related trials consistent with the National Institutes of Health Policy for Data and Safety Monitoring. Every clinical trial conducted at the Siteman Cancer Center must include a plan for data and safety monitoring. In addition, all institutional investigator-initiated clinical trials receive regular stringent quality assurance and safety monitoring. Oversight of data and safety monitoring is the responsibility of the Siteman Cancer Center Quality Assurance and Safety Monitoring Committee (QASMC). The QASMC independently reviews studies and has the power to close or suspend studies as warranted. Decisions, findings, and actions are communicated to the Protocol Review and Monitoring Committee (PRMC) (Section 9.2). The QASMC provides the following services for all institutional investigator-initiated clinical research studies: Independent oversight, performance and review of quality assurance audits Review and oversight of reportable adverse event (RAE) reporting Review and oversight of interim safety and monitoring reports

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30CA091842-13
Application #
8705894
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Zuiani, Adam; Chen, Kevin; Schwarz, Megan C et al. (2016) A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. J Virol 90:10499-10512
Abboud, Ramzi; Keller, Jesse; Slade, Michael et al. (2016) Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. Biol Blood Marrow Transplant 22:1851-60
Johnson, Kimberly J; Zoellner, Nancy L; Gutmann, David H (2016) Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiol 42:53-9
Brownson, Ross C; Dodson, Elizabeth A; Kerner, Jon F et al. (2016) Framing research for state policymakers who place a priority on cancer. Cancer Causes Control 27:1035-41
Chou, Chun; Verbaro, Daniel J; Tonc, Elena et al. (2016) The Transcription Factor AP4 Mediates Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell Responses. Immunity 45:570-82
Durai, Vivek; Murphy, Kenneth M (2016) Functions of Murine Dendritic Cells. Immunity 45:719-736
Beeman, Scott C; Shui, Ying-Bo; Perez-Torres, Carlos J et al. (2016) O2 -sensitive MRI distinguishes brain tumor versus radiation necrosis in murine models. Magn Reson Med 75:2442-7
Mertins, Philipp; Mani, D R; Ruggles, Kelly V et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534:55-62
Niu, Haixia; Hadwiger, Gayla; Fujiwara, Hideji et al. (2016) Pathways of retinoid synthesis in mouse macrophages and bone marrow cells. J Leukoc Biol 99:797-810
Willet, Spencer G; Mills, Jason C (2016) Stomach Organ and Cell Lineage Differentiation: from Embryogenesis to Adult Homeostasis. Cell Mol Gastroenterol Hepatol 2:546-559

Showing the most recent 10 out of 947 publications